Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
OLIGYNE-10 RT is an international registry of adults with gynecologic cancer and a limited number of active sites of cancer spread who receive radiotherapy to at least one metastatic lesion during routine care. The registry combines information from existing medical records with information collected prospectively. Treating clinical teams choose radiotherapy, imaging, systemic treatment, and follow-up. The registry does not assign treatment or require additional imaging or visits. The classical cohort includes people with 1 to 5 active metastatic lesions assessed by computed tomography (CT) or magnetic resonance imaging (MRI), with or without positron emission tomography (PET). An extended, exploratory cohort includes people with 6 to 10 active metastatic lesions assessed by qualifying FDG PET/CT or FDG PET/MRI. Eligible cancers include cervical, endometrial and other uterine cancers, uterine sarcomas, ovarian and fallopian tube cancers, primary peritoneal cancers, vulvar and vaginal cancers, and other eligible rare gynecologic cancers. The main objective is to describe the time from the first qualifying radiotherapy session or brachytherapy application until imaging shows cancer progression at any site or the participant dies. Other objectives include describing the control of treated lesions, patterns of cancer progression, survival, side effects, subsequent treatment of metastases, and how radiotherapy relates to the continuation or change of systemic treatment. The initial target is 500 participants, with possible expansion to at least 1,000. Follow-up is planned for up to five years using information available from routine care.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzona histologicznie pierwszorzędowa choroba nowotworowa ginekologiczna
- •Od 1 do 10 aktywnych ognisk przerzutów
- •Otrzymanie co najmniej jednej sesji radioterapii lub brachyterapii na przerzut
- •Dostępne dane medyczne z napromieniowania i strategii leczenia
- •Dla grupy prospektywnej: zdolność do wyrażenia świadomej zgody
✗ Disqualifies
- •Brak potwierdzonego nowotworu ginekologicznego
- •Tylko operacja, ablacja lub chemioterapia bez radioterapii przerzutów
- •Radioterapia wyłącznie w celu złagodzenia objawów bez zamiaru trwałej kontroli
- •Więcej niż 10 aktywnych ognisk przerzutów
- •Brak wymaganych badań obrazowych do potwierdzenia przerzutów (dla grupy 6-10 zmian)
- •Brak minimalnych danych niezbędnych do oceny kwalifikacji
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Affidea NU-MED Centrum Diagnostyki i Terapii Onkologicznej
Zamość, Poland
Trial contact
Mateusz Bilski, MD, PhD
Paulina Kleban
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.